Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 7/20 | 0.77 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.51 |
| ▸ | RAB9A | P51151 | 2/20 | 0.51 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.51 |
| ▸ | PKM | P14618 | 1/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | DAO | P14920 | 1/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | YEATS4 | O95619 | 1/20 | 0.46 |
| ▸ | ERN1 | O75460 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4157157 | 0.84 | HPGD (0.66) | HPGDALDH1A1L3MBTL1MAPTHRH3 | |
| SCHEMBL17319591 | 0.84 | HPGD (0.66) | HPGDALDH1A1L3MBTL1MAPTNPC1 | |
| SCHEMBL2638071 | 0.81 | HPGD (0.86) | HPGDALDH1A1L3MBTL1MAPTNPC1 | |
| SCHEMBL12121414 | 0.81 | HPGD (0.62) | HPGDALDH1A1L3MBTL1NPC1RAB9A | |
| SCHEMBL12722423 | 0.81 | HPGD (0.77) | HPGDALDH1A1L3MBTL1MAPTNPC1 | |
| SCHEMBL3157121 | 0.80 | HPGD (0.77) | HPGDALDH1A1L3MBTL1MAPTNPC1 | |
| SCHEMBL4111861 | 0.80 | HPGD (0.77) | HPGDALDH1A1L3MBTL1MAPTNPC1 | |
| SCHEMBL16284226 | 0.80 | HPGD (0.57) | HPGDALDH1A1L3MBTL1DAOYEATS4 | |
| SCHEMBL12529261 | 0.80 | YEATS4 (0.75) | HPGDALDH1A1L3MBTL1MAPTNPC1 | |
| SCHEMBL13903187 | 0.80 | HPGD (0.71) | HPGDALDH1A1L3MBTL1MAPTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100216789-A1 | RHO-KINASE INHIBITORS | NAGARATHNAM DHANAPALAN | 2010-08-26 | — | — | US | disclosed |
| US-20100216789-A1 | RHO-KINASE INHIBITORS | NAGARATHNAM DHANAPALAN | 2010-08-26 | — | — | US | disclosed |
| US-7648986-B2 | Substituted thieno[3,2-D]pyrimidines as Rho kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2010-01-19 | — | — | US | disclosed |
| US-7648986-B2 | Substituted thieno[3,2-D]pyrimidines as Rho kinase inhibitors | BAYER HEALTHCARE LLC (US) | 2010-01-19 | — | — | US | disclosed |
| US-20090105292-A9 | Glucocorticoid Receptor Modulator Compounds and Methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2009-04-23 | — | — | US | disclosed |
| EP-1465900-B1 | RHO-KINASE INHIBITORS | BAYER HEALTHCARE AG (DE) | 2008-05-14 | — | — | EP | disclosed |
| US-20070281959-A1 | Glucocorticoid receptor modulator compounds and methods | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2007-12-06 | — | — | US | disclosed |
| US-20070238741-A1 | Hypertension, atherosclerosis, restenosis, cerebral ischemia, cerebral vasospasm, or erectile dysfunction; 2-(5-chloro-2-thienyl)-N-(1H-indazol-5-yl)thieno[3,2-d]pyrimidin-4-amine | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-10-11 | — | — | US | disclosed |
| US-20070238741-A1 | Hypertension, atherosclerosis, restenosis, cerebral ischemia, cerebral vasospasm, or erectile dysfunction; 2-(5-chloro-2-thienyl)-N-(1H-indazol-5-yl)thieno[3,2-d]pyrimidin-4-amine | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2007-10-11 | — | — | US | disclosed |
| CN-1950375-A | Glucocorticoid receptor modulator compounds and methods- utility | LIGAND PHARM INC (US) | 2007-04-18 | — | — | CN | disclosed |
| EP-1718653-A1 | GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY | Ligand Pharmaceuticals Inc. (US) | 2006-11-08 | — | — | EP | disclosed |
| WO-2005082909-A1 | GLUCOCORTICOID RECEPTOR MODULATOR COMPOUNDS AND METHODS- UTILITY | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2005-09-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090105292-A9 | Glucocorticoid Receptor Modulator Compounds and Methods | NR3C1, NR3C2, MC2R | HPGD 272/4885ALDH1A1 1465/4885L3MBTL1 4786/4885 |
| US-20100216789-A1 | RHO-KINASE INHIBITORS | CIT, ROCK1, ROCK2 | HPGD 161/4885ALDH1A1 3561/4885L3MBTL1 3311/4885 |
| US-20070281959-A1 | Glucocorticoid receptor modulator compounds and methods | NR3C1, NR3C2, MC2R | HPGD 272/4885ALDH1A1 1465/4885L3MBTL1 4786/4885 |
| US-20070238741-A1 | Hypertension, atherosclerosis, restenosis, cerebral ischemia, cerebral vasospasm, or erectile dysfunction; 2-(5-chloro-2-thienyl)-N-(1H-indazol-5-yl)thieno[3,2-d]pyrimidin-4-amine | CIT, PTGIS, PTGIR | HPGD 129/4885ALDH1A1 2769/4885L3MBTL1 3976/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.